Abzena is an integrated group offering a broad range of services and technologies to improve the chances of discovering and developing effective biopharmaceutical drugs. With strong footprints in both the US and UK, the company provides a feefor-service offering with the aim of embedding its technology – ‘Abzena Inside’ – into commercial products on which it will derive a long-term royalty stream. To date, from 40 technology agreements, partners have initiated clinical development with 12 ‘Abzena Inside’ products. The service business easily covers the current valuation suggesting that the significant royalty stream is in the price for nothing.
13 Sep 2016
Servicing the royalty stream
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Servicing the royalty stream
Abzena (ABZA:LON) | 0 0 (-0.9%) | Mkt Cap: 54.0m
- Published:
13 Sep 2016 -
Author:
Martin Hall -
Pages:
40
Abzena is an integrated group offering a broad range of services and technologies to improve the chances of discovering and developing effective biopharmaceutical drugs. With strong footprints in both the US and UK, the company provides a feefor-service offering with the aim of embedding its technology – ‘Abzena Inside’ – into commercial products on which it will derive a long-term royalty stream. To date, from 40 technology agreements, partners have initiated clinical development with 12 ‘Abzena Inside’ products. The service business easily covers the current valuation suggesting that the significant royalty stream is in the price for nothing.